# INTERVIEW: Avacta Group – A proven platform with significant upside

- Link: https://www.directorstalkinterviews.com/avacta-group-a-proven-platform-with-significant-upside/412771943
- Published: 2019-04-12T07:15:35+01:00
- Author: Giles Arbor

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group** ([LON: AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l))
CEO Alastair Smith joins DirectorsTalk to discuss interim results for the period
ended 31st Jan 2019. Alastair talks us through the LG Chem deal, shares his thoughts
on the possibility of its collaboration partner Moderna getting an affirmer drug
to clinic first, the progress Avacta are making, why a collaboration with Tufts 
is center in its strategy and expands on a growing pipeline of revenue generating
opportunities.

Avacta’s principal focus is on its proprietary Affimer® technology which is a novel
engineered alternative to antibodies that has wide application in Life Sciences 
for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings.
Affimer® technology has been designed to address many of these negative performance
issues, principally; the time taken to generate new antibodies, the reliance on 
an animal’s immune response, poor specificity in many cases, and batch to batch 
variability. Affimer® technology is based on a small protein that can be quickly
generated to bind with high specificity and affinity to a wide range of protein 
targets.

Avacta Group plc has a pre-clinical biotech development programme with an in-house
focus on immuno-oncology as well as partnered development programmes. Avacta is 
commercialising non-therapeutic Affimer® reagents through licensing to developers
of life sciences research tools and diagnostics.

Share on:
